MedPath

A Study of Ustekinumab in Participants With Active Polymyositis and Dermatomyositis Who Have Not Adequately Responded to One or More Standard-of-care Treatments

Phase 3
Terminated
Conditions
Polymyositis
Dermatomyositis
Interventions
Drug: Ustekinumab 6 mg/kg
Drug: Ustekinumab 90 mg
Drug: Placebo IV
Drug: Placebo SC
Registration Number
NCT03981744
Lead Sponsor
Janssen Pharmaceutical K.K.
Brief Summary

The purpose of this study is to evaluate the efficacy of ustekinumab in participants with active polymyositis (PM)/dermatomyositis (DM) despite receiving 1 or more standard-of-care treatments (for example, glucocorticoids and/or immunomodulators).

Detailed Description

Not available

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
51
Inclusion Criteria
  • Has a diagnosis of polymyositis (PM)/ dermatomyositis (DM) made or confirmed by a physician (such as a rheumatologist, neurologist, or dermatologist) experienced in treatment of PM/DM at least 6 weeks prior to first dose of the study drug
  • Has PM or DM which is considered active despite receiving at least 1 standard-of-care treatment by the investigator
  • Must be receiving 1 or more of the following protocol-permitted, systemic standard-of-care treatments: i) glucocorticoids, ii) 1 or 2 of the following immunomodulatory drugs: mycophenolate mofetil, azathioprine, oral methotrexate, oral tacrolimus, or oral cyclosporine A
  • Regular or as needed treatment with topical use of glucocorticoids are permitted to treat skin lesions on a stable dose for greater than or equal to (>=) 2 weeks prior to first dose of the study drug
  • Contraceptive (birth control) use by men or women should be consistent with local regulations regarding the acceptable methods of contraception for those participating in clinical studies
  • Must be medically stable on the basis of clinical laboratory tests performed at screening. If the results of the clinical laboratory tests are outside the normal reference ranges, the participant may be included only if the investigator judges the abnormalities or deviations from normal to be not clinically significant
  • Demonstrable muscle weakness at screening and Week 0 measured by the Manual Muscle Testing (MMT)-8 less than or equal to (<=)135 units
  • Demonstrable muscle weakness at screening measured by any 2 or more of the followings: (i) PhGA greater than or equal to (>=) 1.5 centimeter (cm), (ii) 1 or more muscle enzymes (Creatine kinase [CK], and aldolase) >=1.4*upper limit of normal (ULN), (iii) Myositis disease activity assessment tool (MDAAT)-Extramuscular Global Assessment >=1.5 cm
Read More
Exclusion Criteria
  • Has myositis other than PM/DM, including but not limited to amyopathic dermatomyositis (ADM), clinically amyopathic DM, juvenile DM, inclusion body myositis (IBM) immune-mediated necrotizing myopathy diagnosed based on muscle biopsy findings and positive anti-SRP or anti-HMGCR antibody, drug-induced myositis, PM associated with human immunodeficiency virus (HIV), and muscular dystrophy, congenital myopathy, metabolic myopathy, and mitochondrial myopathy
  • Has other inflammatory diseases that might confound the evaluations of efficacy, including but not limited to rheumatoid arthritis (RA), psoriatic arthritis (PsA), systemic lupus erythematosus (SLE), psoriasis, or Crohn's disease
  • Has severe respiratory muscle weakness confirmed by the investigator based on the consultation with a pulmonologist and the measures of respiratory muscle strength such as maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP) and/or maximal voluntary ventilation (MVV) measurements and lung capacity such as forced vital capacity (FVC). The results need to be within population appropriate normal limits
  • Has severe muscle damage (Myositis Damage Index-VAS [Muscle Damage] greater than (>) 7 centimeter [cm]), permanent weakness due to a non-IIM cause, or myositis with cardiac dysfunction
  • Has glucocorticoid-induced myopathy which the investigator considers the primary cause of muscle weakness
  • Has positive test result of anti-melanoma differentiation-associated protein 5 (MDA5) antibody (anti clinically amyopathic dermatomyositis (C-ADM)-140 antibody).
  • Has had a nontuberculous mycobacterial infection or opportunistic infection
  • Has a history of, or ongoing, chronic or recurrent infectious disease
  • Has past history of severe Interstitial lung disease (ILD) flare, severe non-infectious lung inflammation which required active intervention, or multiple relapses of these conditions
  • Presence or history of malignancy within 5 years before screening
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Group 1: UstekinumabUstekinumab 90 mgParticipants will receive body weight-range based IV dosing of approximately 6 milligram per kilogram (mg/kg) of ustekinumab at Week 0 followed by ustekinumab 90 milligram (mg) subcutaneously (SC) at Week 8 and every 8 Weeks (q8w) administrations through Week 72. At Week 24, participants will receive IV dosing of placebo.
Group 1: UstekinumabUstekinumab 6 mg/kgParticipants will receive body weight-range based IV dosing of approximately 6 milligram per kilogram (mg/kg) of ustekinumab at Week 0 followed by ustekinumab 90 milligram (mg) subcutaneously (SC) at Week 8 and every 8 Weeks (q8w) administrations through Week 72. At Week 24, participants will receive IV dosing of placebo.
Group 1: UstekinumabPlacebo IVParticipants will receive body weight-range based IV dosing of approximately 6 milligram per kilogram (mg/kg) of ustekinumab at Week 0 followed by ustekinumab 90 milligram (mg) subcutaneously (SC) at Week 8 and every 8 Weeks (q8w) administrations through Week 72. At Week 24, participants will receive IV dosing of placebo.
Group 2: PlaceboUstekinumab 6 mg/kgParticipants will receive IV dosing of placebo at Week 0 followed by placebo SC administrations at Weeks 8,16 and 24. At Week 24, participants will receive body weight-range based IV dosing of approximately 6 mg/kg of ustekinumab, followed by ustekinumab 90 mg SC q8w administrations Week 32 through Week 72.
Group 2: PlaceboUstekinumab 90 mgParticipants will receive IV dosing of placebo at Week 0 followed by placebo SC administrations at Weeks 8,16 and 24. At Week 24, participants will receive body weight-range based IV dosing of approximately 6 mg/kg of ustekinumab, followed by ustekinumab 90 mg SC q8w administrations Week 32 through Week 72.
Group 2: PlaceboPlacebo IVParticipants will receive IV dosing of placebo at Week 0 followed by placebo SC administrations at Weeks 8,16 and 24. At Week 24, participants will receive body weight-range based IV dosing of approximately 6 mg/kg of ustekinumab, followed by ustekinumab 90 mg SC q8w administrations Week 32 through Week 72.
Group 2: PlaceboPlacebo SCParticipants will receive IV dosing of placebo at Week 0 followed by placebo SC administrations at Weeks 8,16 and 24. At Week 24, participants will receive body weight-range based IV dosing of approximately 6 mg/kg of ustekinumab, followed by ustekinumab 90 mg SC q8w administrations Week 32 through Week 72.
Primary Outcome Measures
NameTimeMethod
Percentage of Participants Who Achieved Minimal Improvement in International Myositis Assessment and Clinical Studies Total Improvement Score (IMACS TIS) at Week 24Week 24

Minimal improvement was defined as IMACS TIS greater than or equal to (\>=) 20 in participants with polymyositis (PM)/dermatomyositis (DM). Criteria used the 6 IMACS core set measures: physician global activity (PhGA)(0-10), patient global activity (PtGA)(0-10), manual muscle testing-8 (MMT-8)(0-80), muscle enzymes (creatine kinase, Aldolase, lactate dehydrogenase, aspartate aminotransferase, alanine aminotransferase), extramuscular assessment of myositis disease activity assessment tool (MDAAT)(0-10), and health assessment questionnaire disability index (HAQ-DI)(0-3). Absolute percent change in each core set measure was calculated as final value minus baseline value divided by range\*100. Total improvement score was calculated by sum of 6 core set improvement scores. Total improvement score ranged from 0 to 100 where higher scores indicated greater improvement. This was categorized into 3 categories (minimal \[improvement \>=20\], moderate \[improvement \>=40\] and major \[improvement \>=60\]).

Secondary Outcome Measures
NameTimeMethod
Change From Baseline in Manual Muscle Testing (MMT)-8 Score at Week 24Baseline, Week 24

Change from baseline in MMT-8 score at Week 24 was reported. Manual Muscle Testing was a partially validated tool to assess muscle strength. MMT-8 total score ranged from 0-80, where maximal score was sum of scores from 8 muscle groups (Deltoid middle \[left/right\], Biceps brachii \[left/right\], Gluteus maximus \[left/right\], Gluteus medius \[left/right\], Quadriceps \[left/right\], Wrist extensors \[left/right\], Ankle dorsiflexors \[left/right\], Neck flexors \[axial\]) and each muscle group was scored on a 0 to 10-point scale. The sides (right or left) used for calculating the total score. Higher score indicated greater muscle strength, that is, less impairment of muscle.

Change From Baseline in Functional Index-2 (FI-2) at Week 24Baseline, Week 24

Change from baseline in FI-2 at Week 24 was reported. The FI-2 was a functional outcome developed for participants with adult PM or DM to assess muscle endurance in 7 muscle groups (shoulder flexion \[0-60\], shoulder abduction \[0-60\], head lift \[0-60\], hip flexion \[0-60\], step test \[0-60\], heel lift \[0-120\], and toe lift \[0-120\]). Each muscle group was scored as the number of correctly performed repetitions with 60 or 120 maximal number of repetitions depending on muscle group. The FI-2 was performed unilaterally, preferably on the participant's dominant side for muscle groups of shoulder, hip, and step test. The FI-2 score ranged from 0-60 or 0-120 depending on the muscle group. Higher score indicated better muscle endurance.

Percentage of Participants Who Experienced Disease Worsening Up to Week 24 Based on Consensus Criteria for WorseningUp to Week 24

Percentage of participants who experienced disease worsening up to Week 24 based on consensus criteria for worsening was reported. Criteria for disease worsening in a clinical trial were based on international consensus guideline developed by the IMACS. The worsening of disease was defined as 1 of the following criteria: Worsening of the Physician Global Activity by \>=2 centimeter (cm) on a 10-cm visual analogue scale (VAS) and worsening of findings of MMT-8 by \>= 20 percent (%) from baseline; worsening of MDAAT-global extramuscular organ disease activity (a composite of constitutional, cutaneous, skeletal, gastrointestinal, pulmonary, and cardiac activity) by \>=2 cm on a 10-cm VAS from baseline; worsening of any 3 of 6 IMACS core set (PhGA, PtGA, MMT-8, muscle enzymes, MDAAT, and HAQ-D) activity measures by \>= 30% from baseline.

Change From Baseline in Physician Global Activity (PhGA) at Week 24Baseline, Week 24

Change from baseline in PhGA at Week 24 was reported. Physician Global Activity was a partially validated tool to measure the global evaluation by the physician of the participant's overall disease activity at the time of assessment using a 0-10 cm VAS, where 0 cm= no evidence of disease activity and 10 cm= extremely active or severe disease activity. Negative values indicated improvement from baseline.

Change From Baseline in Extramuscular Assessment by Myositis Disease Activity Assessment Tool (MDAAT) at Week 24Baseline, Week 24

Change from baseline in extramuscular assessment by MDAAT at Week 24 was reported. This validated tool measure the degree of disease activity of extramuscular organ systems and muscle on a 0-10 cm VAS. Extramuscular activity ranged between 0 and 10 via VAS where, 0 cm = absent and 10 cm = maximum disease activity.

Change From Baseline in Muscle Enzyme Levels at Week 24Baseline, Week 24

Change from baseline in muscle enzyme levels (creatine kinase, lactate dehydrogenase) at Week 24 was reported.

Trial Locations

Locations (32)

Fukushima Medical University Hospital

🇯🇵

Fukushima, Japan

Shinko Hospital

🇯🇵

Hyogo, Japan

Tokyo Medical and Dental University Hospital

🇯🇵

Bunkyo-Ku, Japan

Kumamoto University Hospital

🇯🇵

Kumamoto, Japan

Okayama City General Medical Center Okayama City Hospital

🇯🇵

Okayama, Japan

Juntendo University Hospital

🇯🇵

Tokyo, Japan

Nippon Medical School Hospital

🇯🇵

Tokyo, Japan

Nagasaki University Hospital

🇯🇵

Nagasaki-shi, Japan

Kagoshima University Hospital

🇯🇵

Kagoshima City, Japan

Yokohama Rosai Hospital

🇯🇵

Yokohama, Japan

Saga University Hospital

🇯🇵

Saga, Japan

Dokkyo Medical University Hospital

🇯🇵

Shimotsuga-gun, Japan

National Center for Global Health and Medicine

🇯🇵

Tokyo, Japan

Tokyo Medical University Hospital

🇯🇵

Tokyo, Japan

Ehime University Hospital

🇯🇵

Toon, Japan

Fujita Health University Hospital

🇯🇵

Toyoake, Japan

University of Tsukuba Hospital

🇯🇵

Tsukuba, Japan

Yamaguchi University Hospital

🇯🇵

Ube, Japan

Kurashiki Central Hospital

🇯🇵

Kurashiki, Japan

The Jikei University Hospital

🇯🇵

Tokyo, Japan

Tokai University Hospital

🇯🇵

Isehara, Japan

St.Marianna University Hospital

🇯🇵

Kanagawa, Japan

Hospital of the University of Occupational and Environmental Health

🇯🇵

Kita-kyushu, Japan

National Hospital Organization Osaka Minami Medical Center

🇯🇵

Kawachi-Nagano, Japan

Shinshu University Hospital

🇯🇵

Matsumoto, Japan

Minaminagano Medical Center Shinonoi General Hospital

🇯🇵

Nagano, Japan

National Hospital Organization Nagoya Medical Center

🇯🇵

Nagoya-shi, Japan

Niigata University Medical & Dental Hospital

🇯🇵

Niigata, Japan

Kitasato University Hospital

🇯🇵

Sagamihara, Japan

Sakai City Medical Center

🇯🇵

Sakai City, Japan

Tohoku University Hospital

🇯🇵

Sendai-shi, Japan

Tohoku Medical And Pharmaceutical University Hospital

🇯🇵

Sendai, Japan

© Copyright 2025. All Rights Reserved by MedPath